Multiple sclerosis in Ukraine

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system that is one of the most common causes of progressive disability, especially among young people. This, in turn, has a negative impact on both patients and their caregivers. In addition, the overall financial burden on society increases as disability accumulates. At the moment, awareness of MS has increased, more effective methods of therapy have become available, and a significant amount of statistical data has been collected on the epidemiology, diagnosis and treatment of MS in Ukraine and the world. In this article, we want to systematize known epidemiological studies of MS in Ukraine, in particular, using the third edition of The Multiple Sclerosis International Federation (MSIF) Atlas of MS. Clear understanding of the trends and main factors affecting the development and progression of MS in Ukraine, as well as knowledge of the obstacles to access to treatment or rehabilitation of patients with MS, is important for optimal clinical management and improvement of the health care system in our country.

References

1. Confavreux C., Vukusic S., Moreau T. et al. (2000) Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med., 343: 1430–1438.
2. The Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition (September 2020).
3. Zeydan B., Atkinson E.J., Weis D.M. et al. (2020) Reproductive history and progressive multiple sclerosis risk in women. Brain Commun., 2(2): fcaa185.
4. Voskuhl R.R., Sawalha A.H., Itoh Y. (2018) Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression. Mult. Scler., 24(1): 22–31.
5. Thompson A.J., Banwell B.L., Barkhof F. et al. (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol., 17(2): 162–173.
6. Giovannoni G., Lang S., Wolff R. et al. (2020) A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. Neurol. Ther., 9(2): 359–374.
7. Montalban X., Gold R., Thompson A.J. et al. (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler., 24(2): 96–120. doi: 10.1177/1352458517751049.
8. Samjoo I.A., Worthington E., Drudge C. et al. (2021) Efficacy classification of modern therapies in multiple sclerosis. J. Comp. Eff. Res., 10(6): 495–507.
9. European MS Platform (2020) MS Barometer. Brussels: EMSP.
10. Наказ МОЗ України від 11.08.2021 р. № 1723 «Про затвердження номенклатури лікарських засобів, імунобіологічних препаратів (вакцин), медичних виробів (у тому числі медичного обладнання) та допоміжних засобів до них, що закуповуватимуться за бюджетною програмою «Забезпечення медичних заходів окремих державних програм та комплексних заходів програмного характеру» (zakon.rada.gov.ua/go/v1723282-21).
11. Інформація про здійснення державних закупівель лікарських засобів та медичних виробів із залученням спеціалізованих організацій за кошти держбюджету на 2020 і 2021 роки (moz.gov.ua/zakupivli-likiv).
12. health.kyivcity.gov.ua/files/2021/9/14/1203.PDF.
13. lvivoblrada.gov.ua/programi-2021-2025-rokiv.
14. http://www.adm-km.gov.ua/wp-content/uploads/2021/02/%D0%9D%D0%B0%D0%BA%D0%B0%D0%B7-04.02.2021-%D0%B4%D0%BE%D1%80%D0%BE%D0%B3%D0%BE%D0%B2%D0%B0%D1%80%D1%82%D1%96%D1%81%D0%BD%D0%B5.pdf.
15. ror.gov.ua/rishennya-oblasnoyi-radi-8-sklikannya/48-pro-programu-diti-rivnenshini-na-2021-2023-roki-1609408996.
16. Shah P. (2015) Symptomatic management in multiple sclerosis. Ann. Indian Acad. Neurol., 18(Suppl. 1): S35–S42.
17. European Multiple Sclerosis Platform (2012) Recommendations on rehabilitation services for persons with multiple sclerosis in Europe. Brussels: EMSP.